Product image of Imipenem Cilastatin Panpharma (Cilastatin, Imipenem) supplied by GNH India

Imipenem Cilastatin Panpharma

Active Ingredient:
Cilastatin, Imipenem
Origin:
EU

Imipenem Cilastatin Panpharma (Cilastatin, Imipenem)

Imipenem, the active ingredient in Imipenem Cilastatin Panpharma, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats severe bacterial infections, including intra‑abdominal, urinary tract, skin, respiratory and febrile neutropenia, in hospitalized patients. It is administered under medical supervision and is indicated for infections caused by susceptible Gram‑negative and Gram‑positive organisms.

GNH India supplies Imipenem Cilastatin Panpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing regulatory‑approved documentation, reliable logistics and responsive technical support to meet global healthcare needs.

Manufacturer / TM Owner

Panpharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Imipenem/cilastatin is a carbapenem antibiotic used to treat serious bacterial infections.

  • Complicated intra‑abdominal infections: eradicates mixed aerobic and anaerobic pathogens to resolve infection.
  • Complicated urinary tract infections: eliminates resistant Gram‑negative organisms causing pyelonephritis.
  • Skin and soft‑tissue infections: provides broad‑spectrum coverage for severe cellulitis and abscesses.
  • Lower respiratory tract infections (including pneumonia): treats hospital‑acquired and ventilator‑associated pneumonia.
  • Febrile neutropenia: offers rapid bacterial clearance in immunocompromised patients.

How It Works

  • Imipenem binds to bacterial penicillin‑binding proteins, inhibiting the synthesis of the peptidoglycan layer and leading to cell‑wall disruption. Cilastatin, co‑administered, blocks renal dehydropeptidase I, preventing enzymatic degradation of imipenem and thereby maintaining therapeutic plasma concentrations.

Side Effects

Adverse reactions may occur with imipenem/cilastatin therapy.

Common Side Effects

  • Nausea: mild to moderate upset stomach.
  • Diarrhea: may be watery or loose.
  • Headache: transient cranial discomfort.
  • Rash: erythematous skin eruption.
  • Elevated liver enzymes: mild hepatic enzyme rise.
  • Injection site pain: local discomfort during administration.

Serious or Rare Side Effects

  • Seizures: especially in patients with renal impairment.
  • Anaphylaxis: acute, potentially life‑threatening allergic reaction.
  • Clostridioides difficile‑associated diarrhea: severe colitis.
  • Severe neutropenia: marked reduction in white blood cells.
  • Stevens‑Johnson syndrome: extensive skin and mucosal detachment.
  • Renal dysfunction: acute kidney injury in susceptible individuals.

Precautions & Warnings

Use of imipenem/cilastatin requires careful clinical assessment.

  • Assess renal function: dose adjustment may be needed in impaired kidneys.
  • Monitor for seizures: especially in patients with CNS disorders.
  • Evaluate hypersensitivity: discontinue if anaphylactic signs appear.
  • Use cautiously in patients with a history of seizures or epilepsy.
  • Adjust dose in renal impairment: follow prescriber guidance.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Imipenem/cilastatin can interact with several medicines.

Major Interactions (Avoid)

  • Valproic acid: carbapenems reduce serum valproate levels, risking seizure breakthrough.
  • Ganciclovir: concurrent use may lower ganciclovir concentrations.
  • Probenecid: may increase imipenem toxicity by reducing renal clearance.

Moderate Interactions (Monitor Closely)

  • Diuretics: combined use can exacerbate electrolyte disturbances.
  • NSAIDs: may increase risk of renal impairment.
  • Other nephrotoxic agents: monitor kidney function closely.
  • Anticoagulants: potential alteration of INR, require monitoring.

Frequently Asked Questions

Imipenem Cilastatin Panpharma is indicated for severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, skin and soft‑tissue infections, lower respiratory tract infections including pneumonia, and febrile neutropenia in hospitalized patients.

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, leading to cell lysis. Cilastatin prevents renal dehydropeptidase I from breaking down imipenem, thereby maintaining effective drug levels in the bloodstream.

The dosage of Imipenem Cilastatin Panpharma is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Only a qualified healthcare professional should set the dosing regimen.

The safety of Imipenem Cilastatin in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified prescriber.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Imipenem/cilastatin offers a broad spectrum of activity against many Gram‑negative and Gram‑positive bacteria, similar to other carbapenems like meropenem. Its combination with cilastatin protects the drug from renal degradation, allowing higher plasma concentrations, which can be advantageous in certain severe infections.

The product should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Maintaining the cold chain preserves drug stability until reconstitution for intravenous administration.

Imipenem Cilastatin Panpharma is supplied as a sterile powder that must be reconstituted with a suitable diluent and administered intravenously by a healthcare professional, typically as an infusion over a prescribed period.

Serious risks include seizures, especially in patients with renal impairment or CNS disorders, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and rare skin reactions like Stevens‑Johnson syndrome. Prompt medical attention is required if these occur.

Patients with a known hypersensitivity to imipenem, cilastatin, or other carbapenems should avoid this medication. Caution is also advised for individuals with a history of seizures, severe renal impairment, or previous severe allergic reactions to beta‑lactam antibiotics.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cilastatin, Imipenem

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT